❌

Reading view

LLM4AD: Large Language Models for Autonomous Driving - Concept, Review, Benchmark, Experiments, and Future Trends

arXiv:2410.15281v4 Announce Type: replace-cross Abstract: With the broader adoption and highly successful development of Large Language Models (LLMs), there has been growing interest and demand for applying LLMs to autonomous driving technology. Driven by their natural language understanding and reasoning capabilities, LLMs have the potential to enhance various aspects of autonomous driving systems, from perception and scene understanding to interactive decision-making. In this paper, we first introduce the novel concept of designing Large Language Models for Autonomous Driving (LLM4AD), followed by a review of existing LLM4AD studies. Then, we propose a comprehensive benchmark for evaluating the instruction-following and reasoning abilities of LLM4AD systems, which includes LaMPilot-Bench, CARLA Leaderboard 1.0 Benchmark in simulation and NuPlanQA for multi-view visual question answering. Furthermore, we conduct extensive real-world experiments on autonomous vehicle platforms, examining both on-cloud and on-edge LLM deployment for personalized decision-making and motion control. Next, we explore the future trends of integrating language diffusion models into autonomous driving, exemplified by the proposed ViLaD (Vision-Language Diffusion) framework. Finally, we discuss the main challenges of LLM4AD, including latency, deployment, security and privacy, safety, trust and transparency, and personalization.
  •  

Liquid biopsy-derived extracellular vesicle protein biomarkers for diagnosis and prognostic assessment of lung squamous cell carcinoma

Cancer Cell Int. 2025 Apr 24;25(1):161. doi: 10.1186/s12935-025-03792-0.

ABSTRACT

BACKGROUND: For patients with nodules detected in imaging that are indeterminate for malignancy, achieving accurate, early, and non-invasive diagnosis of Lung Squamous Cell Carcinoma (LUSC) remains a significant challenge. Therefore, we aimed to establish diagnostic and prognostic models by identifying plasma extracellular vesicles (EVs) associated protein biomarkers specific to LUSC.

METHODS: This study employed a novel nanomaterial, NaY, for the enrichment of EVs from plasma. Validation was conducted through transmission electron microscopy, nanoparticle tracking analyses, and Western blotting. Machine learning algorithms were utilized to compute protein biomarkers associated with LUSC and establish a diagnostic model. Additionally, a prognostic prediction model for LUSC was developed using a combination of 101 machine learning algorithms. Risk scoring of patients was performed to explore the underlying reasons for prognostic differences between high and low-risk groups.

RESULTS: The results of three experiments demonstrate that the new nanomaterial NaY effectively enriches EVs from plasma. Analysis of the enriched profile reveals pathways related to glycolysis/gluconeogenesis and carbon metabolism enriched in plasma EVs of LUSC patients. Thirty-eight LSCC-related EV biomarkers were identified, from which five proteins (TUBB3, RPS7, RPLP1, KRT2, and VTN) were selected to establish a diagnostic model distinguishing between benign and LUSC nodules. The diagnostic efficacy of RPS7 and VTN was further validated in independent samples using ELISA experiments. Furthermore, DPYD, GALK1, CDC23, UBE2L3, RHEB, and PSME1 were determined as potential prognostic biomarkers. Subsequently, risk scores were computed for each sample, classifying all patients into high and low-risk groups. Enrichment analysis revealed that EVs from the high-risk group contained proteins promoting cell proliferation and invasion, while those from the low-risk group were enriched in immune-related protein biomarkers.

CONCLUSIONS: The novel nanomaterial NaY effectively enriches EVs from plasma. Utilizing plasma EV biomarkers, the diagnostic model demonstrates strong discriminative ability between benign and malignant pulmonary nodules in patients.

PMID:40275246 | PMC:PMC12023671 | DOI:10.1186/s12935-025-03792-0

  •  
❌